A PHASE I/II CLINICAL STUDY TO INVESTIGATE EFFICACY, SAFETY AND PHARMACOKINETICS OF LENALIDOMIDE WITH/WITHOUT DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Iida, S. [1 ]
Nagai, H. [2 ]
Okamoto, S. [3 ]
Chou, T. [4 ]
Takatoku, M. [5 ]
Hotta, T.
机构：
[1] Nagoya City Univ Hosp, Nagoya, Aichi, Japan
[2] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan
[3] Keio Univ, Dept Med, Tokyo, Japan
[4] Niigata Canc Ctr Hosp, Niigata, Japan
[5] Celgene KK, Tokyo, Japan
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1623
引用
收藏
页码：625 / 626
页数：2
相关论文
共 50 条
  • [21] A Phase I Study of Bendamustine Combined with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma.
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Lalo, Silvana
    Kruppa, Carrie
    Gardner, Diane
    Kennedy, Ryan C.
    Burt, Steve
    Mapara, Markus Y.
    Redner, Robert
    Roodman, David
    Volkin, Robert L.
    Zonder, Jeffrey
    BLOOD, 2009, 114 (22) : 736 - 736
  • [22] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Shinsuke Iida
    Takaaki Chou
    Shinichiro Okamoto
    Hirokazu Nagai
    Kiyohiko Hatake
    Hirokazu Murakami
    Toshiyuki Takagi
    Kazuyuki Shimizu
    Henry Lau
    Kenichi Takeshita
    Masaaki Takatoku
    Tomomitsu Hotta
    International Journal of Hematology, 2010, 92 : 118 - 126
  • [23] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Iida, Shinsuke
    Chou, Takaaki
    Okamoto, Shinichiro
    Nagai, Hirokazu
    Hatake, Kiyohiko
    Murakami, Hirokazu
    Takagi, Toshiyuki
    Shimizu, Kazuyuki
    Lau, Henry
    Takeshita, Kenichi
    Takatoku, Masaaki
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 118 - 126
  • [24] The Efficacy and Safety of Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Real Clinical Practice : A Study of the Korean Multiple Myeloma Working Party (KMMWP)
    Lee, Ho Sup
    Min, Chang Ki
    Kim, Kihyun
    Lee, Je-Jung
    Bang, Soo-Mee
    Kim, Jin Seok
    Eom, Hyeon Seok
    Lee, Jae Hoon
    Yoon, Do Hyun
    Kim, Inho
    Shin, Ho-Jin
    Park, Yong
    Jo, Jae-Cheol
    Lee, Won Sik
    Mun, Yeung-Chul
    Kim, Hyo Jung
    Park, Seong Kyu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E74 - E75
  • [25] Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Kraftson, Stephanie
    Ross, Charles W.
    Harvey, Colleen
    Hideshima, Teru
    Sportelli, Peter
    Poradosu, Enrique
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 472 - 480
  • [26] Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
    Alegre, Adrian
    Vicuna, Isabel
    Aguado, Beatriz
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [27] Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Paulus, Aneel
    Alegria, Victoria R.
    Laplant, Betsy
    Moustafa, Muhamad Alhaj
    Chapin, Dustin
    Jackson, Keisha
    Jani, Prachi
    Ahmed, Salman
    Edwards, Brett
    Manna, Alak
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    BLOOD, 2019, 134
  • [28] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
  • [29] Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
    Gupta, Neeraj
    Goh, Yeow Tee
    Min, Chang-Ki
    Lee, Jae Hoon
    Kim, Kihyun
    Wong, Raymond S. M.
    Chim, Chor Sang
    Hanley, Michael J.
    Yang, Huyuan
    Venkatakrishnan, Karthik
    Hui, Ai-Min
    Esseltine, Dixie-Lee
    Chng, Wee Joo
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [30] Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, M. A.
    Swern, A. S.
    Li, J. S.
    Hussein, M.
    Weiss, L.
    Nagarwala, Y.
    Baz, R.
    BLOOD CANCER JOURNAL, 2014, 4 : e257 - e257
12345